RCM
ORKA

RA Capital Management’s Oruka Therapeutics ORKA Stock Holding History

RA Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,075
Closed -$662K – 28
2016
Q4 		$662K Sell
1,075
-1,340
-55% -$713K 0.09% 27
2016
Q3 		$1.48M Sell
2,415
-190
-7% -$122K 0.15% 29
2016
Q2 		$1.63M Sell
2,605
-998
-28% -$739K 0.23% 31
2016
Q1 		$2.7M Hold
3,603
– – 0.35% 36
2015
Q4 		$3.62M Sell
3,603
-153
-4% -$173K 0.36% 34
2015
Q3 		$4.02M Hold
3,756
– – 0.58% 37
2015
Q2 		$6.53M Buy
+3,756
New +$4.94M 0.66% 34

Other funds holding ORKA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RA Capital Management's ORKA Position: Q1 2017 in Review

RA Capital Management sold out of Oruka Therapeutics (ORKA) in Q1 2017, closing a stake of 1,075 shares — an estimated $662K sold.

RA Capital Management first reported a position in ORKA in Q2 2015 and held it in 7 quarters. The position peaked at $6.53M in Q2 2015. 14 funds tracked by Wall St. Rank hold ORKA as of Q1 2017.

  • RA Capital Management reported no remaining Oruka Therapeutics position as of Q1 2017 after selling out during the quarter.
  • RA Capital Management sold 1,075 Oruka Therapeutics shares in Q1 2017, an estimated $662K.
  • RA Capital Management first reported a position in Oruka Therapeutics in Q2 2015 and held it in 7 quarters.
  • RA Capital Management's Oruka Therapeutics position peaked at $6.53M in Q2 2015.
  • 14 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2017.

Based on RA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.